Moexipril Hydrochloride

CHEMBL1200534 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
535.0 g/mol
LogP
Phase
4

A hydrochloride salt of moexipril, an ACE inhibitor used to treat high blood pressure and, in some cases, heart failure. It works by blocking the angiotensin-converting enzyme, relaxing blood vessels and reducing the heart's workload.

Peso molecular

535,0000 g/mol

TPSA

114,00 Ų

Áreas terapéuticas

Mecanismo de acción

Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O.Cl

InChI

InChI=1S/C27H34N2O7.ClH/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32;/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32);1H/t17-,21-,22-;/m0./s1

Molecular Formula

C27H35ClN2O7

HBD / HBA

3 / 8

Enlaces Rotables

12

Átomos Pesados

37

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A hydrochloride salt of moexipril, an ACE inhibitor used to treat high blood pressure and, in some cases, heart failure. It works by blocking the angiotensin-converting enzyme, relaxing blood vessels and reducing the heart's workload.

Inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This reduces peripheral vascular resistance, decreases aldosterone secretion, and lowers blood pressure.

Yes, Moexipril Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200534. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 54889. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.